Payload Information
General Information of This Payload
| Payload ID | PAY0AIAVK |
|||||
|---|---|---|---|---|---|---|
| Name | WO2025015586A1, ADC35, Payload |
|||||
| Synonyms |
compound 8
Click to Show/Hide
|
|||||
| Target | Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8) | |||||
| Structure |
|
|||||
| Formula | C27H38N7O4P |
|||||
| Isosmiles | CCCCC(N1OCCCCNC2=C(NCCNC)C(C2=O)=O)=NC3=C1C4=CC=C(P(C)(C)=O)C=C4N=C3N |
|||||
| InChI |
InChI=1S/C27H38N7O4P/c1-5-6-9-20-33-23-24(18-11-10-17(39(3,4)37)16-19(18)32-27(23)28)34(20)38-15-8-7-12-30-21-22(26(36)25(21)35)31-14-13-29-2/h10-11,16,29-31H,5-9,12-15H2,1-4H3,(H2,28,32)
|
|||||
| InChIKey |
QLDFBFUKAIZJPU-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
555.62 |
Polar area |
153.26 |
||
Complexity |
1533.274467 |
xlogp Value |
2.3055 |
|||
Heavy Count |
39 |
Rot Bonds |
15 |
|||
Hbond acc |
11 |
Hbond Donor |
4 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| The minimum effective concentration (MEC) | 0.137 | uM |
peripheral blood mononuclear cells (PBMCs)
|
Normal
|
[1] | |
| The minimum effective concentration (MEC) | 0.137 | uM |
peripheral blood mononuclear cells (PBMCs)
|
Normal
|
[1] | |
| The minimum effective concentration (MEC) | 1.23 | uM |
peripheral blood mononuclear cells (PBMCs)
|
Normal
|
[1] | |
| The minimum effective concentration (MEC) | 1.23 | uM |
peripheral blood mononuclear cells (PBMCs)
|
Normal
|
[1] |
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
wO2023232144A1ADC39 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Max Tumor Growth lnhibition value (TGl) (d) |
20-50 %
|
Positive TLR expression (TLR+++/++) | ||
| Method Description |
ADC39 was tested in mouse M38 CRC model in C57BL/6 mice, 2.5 mg/kg, QWx3, IV
|
||||
| In Vivo Model | Mouse MC38 CRC Model in C57BL/6 Mice | ||||
wO2023232144A1ADC41 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Max Tumor Growth lnhibition value (TGl) (d) | > 50% | Positive TLR expression (TLR+++/++) | ||
| Method Description |
ADC41 was tested in mouse M38 CRC model in C57BL/6 mice, 2.5 mg/kg, QWx3, IV
|
||||
| In Vivo Model | Mouse MC38 CRC Model in C57BL/6 Mice | ||||
wO2023232144A1ADC43 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Max Tumor Growth lnhibition value (TGl) (d) | > 50% | Positive TLR expression (TLR+++/++) | ||
| Method Description |
ADC43 was tested in mouse M38 CRC model in C57BL/6 mice, 2.5 mg/kg, QWx2, IV
|
||||
| In Vivo Model | Mouse MC38 CRC Model in C57BL/6 Mice | ||||
References